ORBIMED ADVISORS LLC

Position in ABVX — Abivax S.A.

CIK 1055951 New York, NY

Back to ABVX Full portfolio

Position in ABVX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$72,829,521

+$20,973,826 QoQ

Shares Held

546,522

+17.4% QoQ

Ownership

0.626%

of shares outstanding

% of Portfolio

1.44%

of 13F equity value

Holder Rank

#27

of 302 holders

Holding Since

Sep 2025

4 quarters on record

Voting authority Sole 25% Shared 0% None 75%

Common Shares in ABVX Over Time

Shares Held

Position Value (USD)

Derivatives in ABVX

reported options exposure · as of Jun 30, 2026

CallValue

$26,652,000

CallShares

200,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ORBIMED ADVISORS LLC holds $3,639,640,835 across 90 Biotechnology names. ABVX ranks #12 (2.0% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	EWTX	Edgewise Therapeutics, Inc.	15,518,492	$630,516,329
2	ELVN	Enliven Therapeutics, Inc.	6,776,632	$343,914,074
3	MBX	MBX Biosciences, Inc.	3,428,736	$189,266,227
4	GPCR	Structure Therapeutics Inc.	2,209,400	$118,578,498
5	SION	Sionna Therapeutics, Inc.	2,555,877	$112,433,029
6	CRVS	Corvus Pharmaceuticals, Inc.	7,165,006	$107,045,189
7	AVBP	ArriVent BioPharma, Inc.	3,027,328	$105,169,374
8	ARGX	Argenx SE	92,880	$86,171,277

All Filings in ABVX

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$72,829,521	546,522	+17.4%	Shares	Defined	2026-08-14
2026-06-30	$26,652,000	200,000	—	Call	Defined	2026-08-14
2026-03-31	$51,855,695	465,700	+26.6%	Shares	Defined	2026-05-15
2025-12-31	$49,613,154	367,900	-3.2%	Shares	Defined	2026-02-17
2025-09-30	$32,262,000	380,000	—	Shares	Defined	2025-11-14
No filing history on record for this holder in this stock.